Another LMP2-DC vaccine, generated by infecting autologous DCs with an adenovirus vector expressing LMP2 (rAd-LMP2), can elicit CTL responses specific to LMP2 that contribute to preventing the recurrence and metastasis, particularly in the early stage of NPC (Zeng et al., 2020). Here, PSMB9 is linked to nasopharyngeal carcinoma.